Conference Coverage

Tildrakizumab shows positive effects in active psoriatic arthritis

Publish date: July 8, 2019

 

REPORTING FROM EULAR 2019 CONGRESS

SOURCE: Mease PJ et al. Ann Rheum Dis. Jun 2019;78(Suppl 2):77-9. Abstract LB0002, doi: 10.1136/annrheumdis-2019-eular.8669

Pages

Recommended Reading

Obesity might be targetable driver of psoriatic arthritis progression
Psoriatic Arthritis ICYMI
Systemic psoriasis treatments less often prescribed in elderly with psoriasis, despite comparable response rates
Psoriatic Arthritis ICYMI
Infections linked with transition to psoriatic arthritis
Psoriatic Arthritis ICYMI
Psoriatic Arthritis Journal Scan: June 2019
Psoriatic Arthritis ICYMI
PsA Fast Facts: PsA and psoriasis links
Psoriatic Arthritis ICYMI
EULAR keeps csDMARDs as top PsA drugs
Psoriatic Arthritis ICYMI
Unacceptable pain despite inflammation control commonly occurs in PsA patients
Psoriatic Arthritis ICYMI
Flu vaccine succeeds in TNF inhibitor users
Psoriatic Arthritis ICYMI
Ixekizumab boosts quality of life in genital psoriasis
Psoriatic Arthritis ICYMI
Dr. Alexis Ogdie discusses the latest research in psoriatic arthritis
Psoriatic Arthritis ICYMI